Empowering Lung Recovery with Doug Evans of Lungpacer

In this episode, hosts Kyle Kruse and Richard Meiklejohn are joined by Doug Evans, CEO of Lungpacer, to discuss innovative breakthroughs in respiratory care. Doug outlines the critical issue of mechanical ventilation, which affects 2 million patients annually in the U.S., with a 40% mortality rate among them. He provides detailed insights into how Lungpacer's FDA approved neurostimulation technology, AeroPace, aims to improve patient outcomes by maintaining diaphragm muscle function, thereby reducing time on ventilators and minimizing the need for reintubation. The discussion covers the rigorous research and FDA approval process, as well as the forthcoming AeroNova system, in development, designed to assist patients from the onset of mechanical ventilation. Doug also shares the company's plans for commercialization, manufacturing scale-up, and future clinical milestones. The conversation highlights the potential impact of Lungpacer’s technology on patient survival rates and healthcare costs, positioning it as a transformative solution in critical care, a story sure to leave you informed and inspired.